1. In Vivo
  2. >>Global Vision

Edwards’ Success With Go-Slow Sapien Launch

Transcatheter heart valves (TAVI) arrived in Europe in 2007 with the introduction of Medtronic PLC’s CoreValve, followed shortly thereafter by Edwards Lifesciences Corp.’s Sapien. (SeeAlso see "CoreValve: A Surgeon Moves Heart Valves to the Cath Lab" - In Vivo, 1 March, 2007., [A#2012800185] andAlso see "Edwards: Transcatheter Valve Leader Proves You Can Go Home Again " - In Vivo, 1 November, 2010..) Designed to treat patients with severe, symptomatic aortic stenosis, these innovative therapies have the potential to treat inoperable patients and eventually those considered high-risk for traditional surgery, creating market potential of $10+ billion per year.

In the US, Edwards had a sizeable head start, launching in late 2011, while competitors were still seeking regulatory approval....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.